// App-Quantinova.ai

: A Modeling and Simulation Approach to Further Characterize the Efficacy of Low-Dose Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes (T1DM)

Researchers

Presenter

  • BRUCE A. PERKINS

Principal Investigators

  • NIMA SOLEYMANLOU

  • JULIO ROSENSTOCK

  • JAY S. SKYLER

  • LORI M. LAFFEL

  • KARL-HEINZ LIESENFELD

  • DIETMAR NEUBACHER

  • MATTHEW RIGGS

  • CURTIS K. JOHNSTON

  • RENA J. EUDY-BYRNE

  • AHMED ELMOKADEM

  • JYOTHIS GEORGE

  • JAN MARQUARD

Medical Centers

  • N/A

Locations

  • Canada

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Endocrine/metabolic Diseases (ME)

Disease

  • Diabetic ketoacidosis

  • Type 1 diabetes mellitus

  • Diabetes

  • Type 2 diabetes mellitus

Biomarkers

  • Hemoglobin A1c

  • Insulin

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved